Drano, with respect, while I personally believe the data can be salvaged the outlay to rectify might suggest a better investment in a monotherapy trial which would be more of a slam dunk and is a much larger market. That said, the damage is still there and is great…IMHO in the hundreds of millions or perhaps in excess of a billion. Our market cap was over a billion once. Damage has to also be measured in lost opportunities…had we been to market, higher share price and easier to fund clinical trials we might have had phase 3 NASH results by now. The damages are there whether the HIV trial data can be salvaged or not. I’m sure Sidley has a black binder FULL of damage arguments.